Special Issue

Topic: Epidemiology and Natural History of Non-Alcoholic Liver Disease

A Special Issue of Hepatoma Research

ISSN 2454-2520 (Online) 2394-5079 (Print)

Submission deadline: 31 Aug 2020

Guest Editor(s)

Stefano Bellentani, MD, PhD
Independent Consultant Hepatologist and Gastroenterologist Studio Gastro Lugano/Chiasso and Ambulatorio Medico Locarno, Ticino, Switzerland; Fondazione Italiana Fegato (FIF) Trieste, Italy.

Special Issue Introduction

Non-Alcoholic Liver Disease (NAFLD) is an emerging chronic liver disease correlated to insulin resistance and dysmetabolic disease worldwide. The global epidemiology is almost well-designed as far as concerning the prevalence but not for the incidence and the natural history. NAFLD/NASH (non-alcoholic steato-hepatitis) is the second indication for liver transplant in USA nowadays. We know that the liver-correlated cause of mortality of patients with NAFLD is only the third leading cause of death, the first cause is cardiovascular diseases and the second is colonic cancer in men and breast cancer in women.
The scientific community still does not have in his hands all the appropriate tools to make a correct non-invasive diagnosis to identify patients with NAFLD who can evolve in NASH or to understand who is going to progress more or less rapidly towards fibrosis/cirrhosis and/or hepatocellular carcinoma (HCC) or towards cardiovascular disease or cancer.
A lot of work must be still done both in the definition and classification of NAFLD and NASH and in identifying patients at risk to evolve towards a more aggressive form of liver disease or to die. Surveillance policy for population at risk is not yet applicable in the real practice. Finally, no effective treatments are still on the market even if more than 250 clinical trials on new drugs are ongoing worldwide.
In this Special Issue of Hepatoma Research, the real Global Epidemiology and Natural History, and new updated insights especially in the actual incidence and future trends of this new epidemic burden will be discussed by the major experts in this field.

Potential topics include, but are not limited to the following titles.
1. The global Prevalence of NAFLD and NASH
2. It is time for a New Definition of NAFLD/NASH?
3. The global Incidence of NAFLD/NASH and trend for the future
4. The "Juvenile NASH": fact or fiction?
5. The Natural History of NAFLD patients evolving to Cardiovascular Diseases (CVD)
6. The Natural History of NAFLD patients evolving to not-liver related Cancer
7. The Natural History of NAFLD patients evolving to end-stage liver diseases
8. The prevalence of Hepatocellular Carcinoma (HCC) in patients with NASH
9. The prevalence of HCC in patients with Diabetes or Obesity
10. The future trend of NAFLD/NASH: global burden epidemic or fake-news?
11. Future prospective for a better diagnosis and prognosis of NASH/NAFLD

Submission Deadline

31 Aug 2020

Submission Information

For Author Instructions, please refer to https://oaepublish.com/hr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=hr&SpecialIssueId=402
Submission Deadline: 31 Aug 2020
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net

Published Articles

Open Access Review

Role of CD4+ T-cells in the pathology of non-alcoholic fatty liver disease and related diseases

Hepatoma Res 2021;7:46.
DOI: 10.20517/2394-5079.2021.46
Published on: 23 May 2021
Open Access Opinion

Mechanisms of protective effects of astaxanthin in nonalcoholic fatty liver disease

Hepatoma Res 2021;7:30.
DOI: 10.20517/2394-5079.2020.150
Published on: 8 Apr 2021
Open Access Perspective

Prospects for a better diagnosis and prognosis of NAFLD: a pathologist´s view

Hepatoma Res 2021;7:27.
DOI: 10.20517/2394-5079.2020.137
Published on: 8 Apr 2021
Open Access Systematic review

Systematic review of existing guidelines for NAFLD assessment

Hepatoma Res 2021;7:25.
DOI: 10.20517/2394-5079.2021.03
Published on: 6 Apr 2021
Open Access Review

Clinical implications of hepatic progenitor cell activation in non-alcoholic fatty liver disease

Hepatoma Res 2021;7:15.
DOI: 10.20517/2394-5079.2020.119
Published on: 2 Feb 2021
Open Access Original Article

Steatosis/steatohepatitis: how sustainable is the non-invasive instrumental differential diagnosis in clinical practice?

Hepatoma Res 2021;7:14.
DOI: 10.20517/2394-5079.2020.115
Published on: 2 Feb 2021
Open Access Review

Novel high-throughput applications for NAFLD diagnostics and biomarker discovery

Hepatoma Res 2021;7:2.
DOI: 10.20517/2394-5079.2020.92
Published on: 6 Jan 2021
Open Access Review

Genetic risk factors associated with NAFLD

Hepatoma Res 2020;6:85.
DOI: 10.20517/2394-5079.2020.96
Published on: 4 Dec 2020
Open Access Review
Open Access Review

Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential

Hepatoma Res 2020;6:82.
DOI: 10.20517/2394-5079.2020.88
Published on: 4 Dec 2020
Open Access Review

Prevalence and incidence of intra- and extrahepatic complications of NAFLD in patients with type 2 diabetes mellitus

Hepatoma Res 2020;6:78.
DOI: 10.20517/2394-5079.2020.75
Published on: 5 Nov 2020
Open Access Original Article

The transcontinental variability of nonalcoholic fatty liver disease

Hepatoma Res 2020;6:72.
DOI: 10.20517/2394-5079.2020.73
Published on: 11 Oct 2020
Open Access Commentary
Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)


All published articles are preserved here permanently:



All published articles are preserved here permanently: